Frequent longitudinal blood microsampling and proteome monitoring identify disease markers and enable timely intervention in a mouse model of type 1 diabetes
Diabetologia, 2025
Parajuli A., Bendes A., Byvald F., Stone V., Ringqvist E., Butrym M., Angelis E., Kipper S., Bauer S., Roxhed N., Schwenk J., Flodström-Tullberg M.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Metabolic Diseases Infectious Diseases | Pathophysiology | Dried Blood Spots |  Olink Target 96 Mouse |
Abstract
Aims/hypothesis
Type 1 diabetes manifests after irreversible beta cell damage, highlighting the crucial need for markers of the presymptomatic phase to enable early and effective interventions. Current efforts to identify molecular markers of disease-triggering events lack resolution and convenience. Analysing frequently self-collected dried blood spots (DBS) could enable the detection of early disease-predictive markers and facilitate tailored interventions. Here, we present a novel strategy for monitoring transient molecular changes induced by environmental triggers that enable timely disease interception.
Methods
Whole blood (10 μl) was sampled regularly (every 1–5 days) from adult NOD mice infected with Coxsackievirus B3 (CVB3) or treated with vehicle alone. Blood samples (5 μl) were dried on filter discs. DBS samples were analysed by proximity extension assay. Generalised additive models were used to assess linear and non-linear relationships between protein levels and the number of days post infection (p.i.). A multi-layer perceptron (MLP) classifier was developed to predict infection status. CVB3-infected SOCS-1-transgenic (tg) mice were treated with immune- or non-immune sera on days 2 and 3 p.i., followed by monitoring of diabetes development.
Results
Frequent blood sampling and longitudinal measurement of the blood proteome revealed transient molecular changes in virus-infected animals that would have been missed with less frequent sampling. The MLP classifier predicted infection status after day 2 p.i. with over 90% accuracy. Treatment with immune sera on day 2 p.i. prevented diabetes development in all (100%) of CVB3-infected SOCS-1-tg NOD mice while five out of eight (62.5%) of the CVB3-infected controls treated with non-immune sera developed diabetes.
Conclusions/interpretation
Our study demonstrates the utility of frequently collected DBS samples to monitor dynamic proteome changes induced by an environmental trigger during the presymptomatic phase of type 1 diabetes. This approach enables disease interception and can be translated into human initiatives, offering a new method for early detection and intervention in type 1 diabetes.
Data and code availability
Additional data available at https://doi.org/10.17044/scilifelab.27368322. Additional visualisations are presented in the Shiny app interface https://mouse-dbs-profiling.serve.scilifelab.se/.